Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $12.80

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received a consensus rating of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $12.80.

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Leerink Partners increased their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Barclays raised their price target on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th.

Insider Activity

In related news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider directly owned 1,356,053 shares of the company’s stock, valued at $11,526,450.50. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total transaction of $141,494.34. Following the transaction, the insider owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. This trade represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 224,998 shares of company stock worth $1,847,219. 4.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of the stock. Allworth Financial LP acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $34,000. KBC Group NV acquired a new position in Xeris Biopharma during the 1st quarter worth $27,000. State of Wyoming bought a new position in Xeris Biopharma in the 2nd quarter valued at $52,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Xeris Biopharma in the 2nd quarter valued at $74,000. Finally, Kingsview Wealth Management LLC acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $78,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Stock Down 0.8%

Shares of NASDAQ:XERS opened at $8.66 on Monday. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The company’s fifty day moving average is $8.35 and its 200-day moving average is $7.13. The company has a market capitalization of $1.58 billion, a PE ratio of -78.73 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Equities research analysts predict that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company’s commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome.